Authors

William J. Gradishar, MD, Northwestern University

Latest:

Therapeutic Advances in Prophylaxis Against CIN

An overview of therapies used as prophylaxis against chemotherapy-induced neutropenia and projections on improving quality of life for patients with solid tumors with therapeutic advances.

William K. Kelly, DO

Latest:

Dr. Kelly on the Next Steps With Radium-223 and Niraparib in mCRPC

William K. Kelly, DO, discusses the next steps with the combination of radium-223 dichloride and niraparib in metastatic castration-resistant prostate cancer.

William K. Oh, MD

Latest:

Dr. Oh on Challenges With Developing Novel Targeted Agents in Prostate Cancer

William K. Oh, MD, discusses challenges with developing novel targeted agents in prostate cancer.

William Kevin Kelly, DO

Latest:

Dr. Kelly on Radium-223 Dichloride and Niraparib in Patients With mCRPC

William K. Kelly, DO, discusses results from a phase 1b dose-finding study (NCT03076203) evaluating the combination of radium-223 dichloride (Xofigo) plus niraparib (Zejula) in patients with metastatic castration-resistant prostate cancer.

William L. Dahut, M

Latest:

Dr. Dahut on the Future of Genetic Screening in Prostate Cancer

William L. Dahut, MD, discusses the future of genetic screening in prostate cancer.

William L. Dahut, MD

Latest:

Dr. Dahut on the Future of Genetic Screening in Prostate Cancer

William L. Dahut, MD, discusses the future of genetic screening in prostate cancer.

William M. Grady, MD

Latest:

Dr. Grady on Gene Profiling of CTCs in Pancreatic Cancer

William M. Grady, MD, from the Fred Hutchinson Cancer Research Center, discusses results from an ongoing prospective study looking at gene expression profiling of circulating tumor cells in patients with unresectable pancreatic cancer.

William Oh, MD

Latest:

Dr. Oh on the Management of Hormone-Sensitive Prostate Cancer

William Oh, MD, chief, Division of Hematology and Medical Oncology, professor of medicine and urology, Mount Sinai School of Medicine, discusses the management of patients with hormone-sensitive prostate cancer.

William Oh, MD, Mount Sinai Health System

William P. Tew, MD

Latest:

Dr. Tew Evaluates Avastin Treatment in Ovarian Cancer

William P. Tew, MD, a Gynecologic Medical Oncologist at Memorial Sloan-Kettering Cancer Center in New York, evaluates bevacizumab (Avastin) as a treatment for women with ovarian cancer

William Pass, DVM

Latest:

Direct Targeting of RET Aberrations Moves Closer to the Clinic

Over the past 30 years, from the discovery of a fusion rearrangement to the recent promise of LOXO-292, RET targeting has gone from distant concept toward clinical reality.

William R. Berry, MD

Latest:

Dr. Berry on Novel Imaging Techniques for Prostate Cancer

William R. Berry, MD, medical oncologist, Duke University, discusses novel imaging techniques for patients with prostate cancer.

William R. Gwin III, MD

Latest:

Dr. Gwin on Potential Areas of Investigation With Alpha-TEA/Trastuzumab in Breast Cancer

William R. Gwin III, MD, discusses potential areas of investigation with the combination of alpha-tocopheryloxyacetic acid (alpha-TEA) and trastuzumab (Herceptin) in breast cancer.

William R. Jarnagin, MD

Latest:

Dr. Jarnagin on Surgical Protocols for CRC That Have Spread Beyond the Liver

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the surgical barriers in treating patients with colorectal cancer that has metastasized outside of the liver.

William R. Jarnagin, MD, FACS

Latest:

Dr. Jarnagin on the Improvements in Surgery for Patients With mCRC

William R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer.

William Robinson, MD

Latest:

Palliative Care Issues in Gynecologic Cancer

Palliative care should address the unique symptom profile of gynecologic cancer and be tailored to individual socioeconomic environments.

William Sikov

Latest:

Dr. Sikov on Bevacizumab or Carboplatin Impact On TNBC Subtype

William T. DeRosa, DO

Latest:

Dr. DeRosa Discusses Nab-Paclitacel in Lung Cancer

William T. DeRosa, DO, from Carol G. Simon Cancer Center at Morristown Memorial Hospital, discusses subset analyses from the phase III CA031 trial that examined nab-paclitaxel in non-small cell lung cancer.

William T. Lowrance, MD

Latest:

The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations

Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.

William Tew, MD

Latest:

Individualized Approach to Treatment for the Elderly Ovarian Cancer Patient

Stuart Lichtman, MD, and William Tew, MD, from Memorial Sloan-Kettering Cancer Center, discuss personalizing treatment for elderly patients with ovarian cancer.